Femasys partners CapexMD to finance FemaSeed fertility access

Femasys has announced a commercial partnership with CapexMD, a US specialty finance company focused exclusively on fertility care, to provide dedicated patient financing for the company's FemaSeed-led fertility portfolio. The arrangement covers FemaSeed Complete, the company's in-office intratubal insemination system, alongside its companion diagnostics FemVue and SpermVue, and is intended to extend access across OB/GYN practices and fertility centres.

Femasys, listed on NASDAQ under the ticker FEMY, positions FemaSeed as a lower-cost first-line alternative to in vitro fertilisation. The company argues that treatment cost remains a meaningful barrier even for patients who might otherwise qualify for less intensive interventions, and the financing arrangement is designed to address that gap without requiring patients to pursue IVF referrals.

Kathy Lee-Sepsick, founder and chief executive of Femasys, said the CapexMD tie-up "adds an important financing option that can help reduce that barrier and allow more patients to move forward with care," framing the partnership as consistent with the company's broader goal of making earlier, less invasive fertility treatment a practical rather than aspirational option.

The portfolio

FemaSeed Complete pairs the FemaSeed intratubal insemination device with FemSperm, an in-office sperm handling system, allowing a practice to deliver first-line fertility treatment without outsourcing to a specialist laboratory. FemVue uses ultrasound to assess fallopian tube patency, while SpermVue is positioned as an at-home male fertility screening tool. Together, Femasys describes the portfolio as supporting a continuous care pathway from initial diagnostic evaluation through to treatment.

CapexMD's financing model can consolidate costs across multiple providers, including medications, genetic testing, cryopreservation and donor services, into a single loan product. A.J. Rosenfield, Client Relations Director at CapexMD, said the firm has spent more than 17 years focused solely on fertility financing, and described the Femasys agreement as an extension of its mission to prevent financial considerations from becoming "an unnecessary barrier to moving forward with care."

Market context

The partnership arrives at a moment of growing commercial and policy attention on fertility access in the United States. Employer-sponsored IVF benefit coverage has expanded markedly over the past three years, but that expansion has largely benefited patients at larger companies with comprehensive health plans. Patients in OB/GYN settings, particularly those in rural or underserved markets, frequently lack equivalent coverage and are more likely to rely on personal financing. Femasys is explicitly targeting this cohort by enabling fertility care within existing OB/GYN infrastructure rather than requiring specialist referral.

Several medical device and diagnostics companies have pursued analogous strategies in adjacent reproductive health categories, embedding financing partnerships directly at the point of care to reduce abandonment. The competitive landscape for lower-cost fertility intervention is nonetheless still nascent; IUI has historically been underserved by dedicated device development, which gives Femasys a degree of runway that a more crowded field would not.

The company is separately advancing FemBloc, a non-surgical permanent birth control device, through its pivotal FINALE trial for US FDA approval. FemBloc has already received regulatory clearance in Europe, the UK and New Zealand. That parallel programme means Femasys is carrying both a commercialisation story and a late-stage regulatory narrative simultaneously, a combination that adds complexity but also broadens the investor case beyond a single product line.